European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

Description du projet

Combiner la génétique et l’imagerie pour découvrir des médicaments contre la MA

Les essais cliniques sur de nouveaux médicaments contre la maladie d’Alzheimer (MA) n’ont montré aucune efficacité pour ralentir sa progression, soulignant l’importance de nouvelles cibles thérapeutiques. Pour atteindre cet objectif, le projet MAP-AD, financé par l’UE, utilisera des variantes génétiques des chromosomes autosomique et X pour identifier de nouvelles voies moléculaires et des cibles thérapeutiques supposées. Les chercheurs décrypteront l’impact de variantes génétiques spécifiques sur l’expression des gènes grâce à l’analyse des tissus cérébraux post-mortem. Combinées à l’analyse d’imagerie cérébrale multimodale, les informations génomiques seront appliquées pour inscrire correctement les patients aux essais cliniques, ce qui accélèrera le développement de médicaments pour la prévention et le traitement de la MA.

Objectif

Alzheimer’s disease (AD) is a major societal challenge, impacting up to one third of the population over 85 years old. The European Commission and various international bodies have repeatedly fostered research initiatives to prevent the development or stem the progression of the disease. Several recent phase 3 clinical trials have failed to show any efficacy in slowing disease progression, calling into question the current drug targets. This project will use genetic data to identify new AD-relevant molecular pathways and their associated drug targets. Given the increased risk of AD in women, we will apply our innovative analyses not only to autosomal variants but also to X-chromosome variants as well. The mechanistic effects of genetic variants on pathogenesis will be delineated using gene expression from post-mortem brain tissue and AD biomarkers derived from multimodal brain imaging studies. These in-vivo PET and MRI biomarkers are essential for enrolling patients correctly in clinical trials and assessing the effect of treatments on disease progression. We will assess whether a polygenic risk score, based on thousands of genetic variants, will be useful in predicting an individual’s clinical and biomarker progression over time. This project is markedly interdisciplinary in nature between its analysis of multimodal brain imaging and genomics data, and the combination of big data analysis guided by expert medical knowledge of the pathogenesis. Results have the potential to (i) identify new drug targets and (ii) strengthen clinical trial design, thereby speeding the development of drugs for the prevention and treatment of AD. This fellowship represents a unique opportunity to transfer knowledge and analysis methods of next generation genomics AD data from one of the leading US groups in integrating multimodal imaging and genomics data to the European AD research community.

Mots‑clés

Coordinateur

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
Contribution nette de l'UE
€ 257 619,84
Adresse
BOULEVARD DE L'HOPITAL 47
75013 Paris
France

Voir sur la carte

Région
Ile-de-France Ile-de-France Paris
Type d’activité
Research Organisations
Liens
Coût total
€ 257 619,84

Partenaires (1)